

# 2nd Annual BREAST CANCER SYMPOSIUM



## Controversies in Breast Cancer: Increasing or Decreasing?

### Friday, September 25th, 2020

10:00 AM	EXHIBITS	
10:15 AM	Non-CME Session: Navigating the HER2+ Breast Cancer Treatment Landscape: A Case-Based Clinical Discussion	Dr. Brian Leyland-Jones (National Foundation for Cancer Research)
11:15 AM	Non-CME Session: A CEK 4 & 6 Inhibitor With Overall Survival Data for Women With HR+, HER2-Metastatic Breast Cancer, Including Those Likely to Do Worse	Dr. Peter Kaufman (University of Vermont Cancer Center, Burlington)
12:00 PM	Welcome, Opening Remarks & Arena Survivorship Award	Dr. Maria Theodoulou (NYOH) Dr. Ira Zackon (NYOH)
12:30 PM	COVID19 & The Physician	Dr. Marc Citron (ProHEALTH)
1:00 PM	Breast Imaging: Current & Future	Dr. Elizabeth Morris (MSKCC)
1:30 PM	EXHIBITS & BREAK	
1:45 PM	Community Driven Breast Imaging	Dr. Beth Whiteside (CCP)
2:15 PM	Hereditary Risk Factors in 2020	Dr. Mark Robson (MSKCC)
2:45 PM	Metabolic & Energy Balance Perturbations in Breast Cancer Pathogenesis & Treatment	Dr. Neil Iyengar (MSKCC)
3:45 PM	EXHIBITS & BREAK	
4:00 PM	Advances in the Management of Hormone Positive Early Breast Cancer	Dr. Francis Arena (NYU)
4:30 PM	Assessing Risk for Breast Cancer & Intervention	Dr. Andrew Seidman (MSKCC)
5:00 PM	Advances in the Management of Hormone Positive Metastatic Breast Cancer	Dr. Claudine Isaacs (Georgetown)
5:30 PM	EXHIBITS & BREAK	
5:45 PM	Breast Cancer & The Older Patient	Dr. Hyman Muss (UNC)
6:15 PM	Triple Negative Breast Cancer Management in 2020: Looking Back & Looking Ahead	Dr. Tiffany Traina (MSKCC)
6:45 PM	DAY 1 CLOSING REMARKS	Dr. Maria Theodoulou (NYOH)
6:55 PM	Non-CME Session: Innovative Oral Treatment Options for Patients: HR+/HER2- mBC or gBRCA Mutated Triple-Negative and HR+/HER2- mBC	Dr. Anne Porter O'Dea (University of Kansas Cancer Center)

### Saturday, September 26th, 2020

7:00 AM	EXHIBITS	
8:00 AM	Opening Remarks	Dr. Maria Theodoulou (NYOH)
8:05 AM	What Do We Do With the Lymph Nodes after Neo-Adjuvant Chemotherapy: Case Discussion	Dr. Eleftherios Mamounas (UF) Dr. Loren Rourke (US Oncology)
8:35 AM	Immunotherapy and Breast Cancer	Dr. George Plitas (MSKCC)
9:05 AM	Breast Reconstruction in the Setting of Adjuvant Radiation	Dr. Joseph Disa (MSKCC)
9:35 AM	Radiation Therapy After Neoadjuvant Chemotherapy	Dr. Todd Doyle (NYOH)
10:05 AM	Hypofractionation If At All	Dr. Yasmin Hasan (UOC)
10:35 AM	EXHIBITS & BREAK	
10:50 AM	KEYNOTE LECTURE: What is Cancer?	Dr. Larry Norton (MSKCC)
11:50 AM	EXHIBITS	
12:00 PM	Non-CME Session: Updates on the Treatment of Patients With Unresectable or Metastatic HER2+ Breast Cancer Who Previously Received Anti-HER2 Therapies	Dr. Marc Citron (ProHEALTH)
1:00 PM	Tailoring Adjuvant Therapy for Early Stage HER2+ Breast Cancer	Dr. Edith Perez (MAYO)
1:30 PM	HER2NEU Metastatic Breast Cancer	Dr. Chau Dang (MSKCC)
2:00 PM	DAY 2 CLOSING REMARKS	Dr. Maria Theodoulou (NYOH)
2:10 PM	Non-CME Session: TUKYSA® (tucatinib): A New Treatment Option for Patients with HER2+ Metastatic Breast Cancer	Dr. Virginia Kaklamani (UT Health)